About this trial
Migraine is a common disabling neurological condition that significantly affects quality of life. While traditional prophylactic treatments (e.g., beta-blockers, antiepileptics) are effective, they may be associated with side effects leading to poor adherence. Recent evidence suggests that nutraceuticals like magnesium, riboflavin, and coenzyme Q10 may provide a safer alternative. This study aims to compare the efficacy and tolerability of these two approaches.
Eligibility criteria
Qualifiers
Adults aged 18-60 years
- Diagnosed with episodic migraine (ICHD-3 criteria)
- ≥4 migraine attacks/month for the past 3 months
- Willing to provide informed consent
Disqualifiers
• - Chronic migraine (>15 headache days/month)
- Use of other prophylactic treatments in past month
- History of secondary headaches
- Pregnancy or breastfeeding
Trial design
Treatments tested in this trial
- Propranolol 80 mg
- Magnesium 400Mg